Cancer-Associated Thrombosis: From Biomarkers to Diagnostic and Therapeutic Strategies to Optimize Treatment

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 974

Special Issue Editors


E-Mail
Guest Editor
Pulmonary Unit, Cardiothoracic and Vascular Department, Pisa University Hospital, 56124 Pisa, Italy
Interests: pulmonary embolism; lung cancer; extracellular vesicles tissue factor; anticoagulant; chest imaging

E-Mail
Guest Editor
Arianna Anticoagulation Foundation, Bologna, Italy
Interests: coagulation; thrombosis; cardiology; pulmonary embolism; phlebology

E-Mail Website
Guest Editor
Arianna Anticoagulazione Foundation, 40138 Bologna, Italy
Interests: thrombosis; venous thromboembolism; pulmonary embolism; blood coagulation; platelets; hematology; coagulation; atrial fibrillation

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “Cancer-Associated Thrombosis: From Biomarkers to Diagnostic and Therapeutic Strategies to Optimize Treatment”, aims to focus on the role of emerging biomarkers and the pathophysiological mechanisms, clinical manifestations, and novel diagnostic and therapeutic approaches of thromboembolism in cancer patients.

Cancer-related thromboembolism (CAT) is an epidemiologically growing disease that has a major impact on patient morbidity and mortality, as well as on economic and human resources. Interest in this issue is strong, and we need to improve our knowledge about pathophysiological mechanisms, the identification of disease markers with clinical implications, and the optimization of diagnostic and therapeutic pathways in order to improve the management of each individual patient. There are a lot of gaps in the literature, so innovation needs to be continued in this field.

This Special Issue welcomes the submission of both clinical and basic research in the form of original articles and reviews regarding pathophysiology and the molecular mechanisms of cancer-related thrombosis (pulmonary embolism, venous thrombosis, etc.), the peculiarities associated with the individual tumor site (for example, thrombotic or hemorrhagic risk), and traditional and innovative diagnostic and therapeutic approaches to improve basic knowledge and clinical management.

Dr. Roberta Pancani
Dr. Gualtiero Palareti
Dr. Emilia Antonucci
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer-associated thrombosis
  • venous thrombosis
  • biomarkers
  • pulmonary embolism
  • precision medicine
  • diagnostic optimization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 1673 KB  
Systematic Review
Exploring the Association Between Pulmonary Hypertension and Cancer: A Systematic Review and Meta-Analysis
by Filippo Catalani, Arianna Pannunzio, Emanuele Valeriani, Walter Ageno, Pasquale Pignatelli and Sandor Györik
Biomedicines 2026, 14(4), 876; https://doi.org/10.3390/biomedicines14040876 - 11 Apr 2026
Viewed by 515
Abstract
Background: Cancer and pulmonary circulation disorders represent increasingly intersecting clinical entities. The prevalence of malignancy in patients with pulmonary hypertension (PH), particularly those with chronic thromboembolic pulmonary hypertension (CTEPH), is higher than in the general population. Moreover, cancer and antineoplastic therapies have been [...] Read more.
Background: Cancer and pulmonary circulation disorders represent increasingly intersecting clinical entities. The prevalence of malignancy in patients with pulmonary hypertension (PH), particularly those with chronic thromboembolic pulmonary hypertension (CTEPH), is higher than in the general population. Moreover, cancer and antineoplastic therapies have been implicated in the development of PH through multiple mechanisms. Methods: We performed a systematic review and meta-analysis of the literature focusing on the prevalence of cancer in patients with PH. Mortality incidence and mortality risk were also evaluated for patients with PH with or without cancer. Specific sub-analyses for patients with CTEPH were also performed. Finally, we evaluated the prevalence of PH and its risk of mortality in patients with cancer. Results: Overall, 12 studies including 4402 patients were selected in the quantitative analysis. All the included studies had an observational design. The prevalence of cancer in patients with any PH group was 13% (95% CI: 11–16%); mortality incidence in patients with any PH group and cancer was 41% (95% CI: 26–58%), compared to 10% (95% CI: 1–48%) in those without cancer. The association was even stronger when considering only patients with CTEPH, with a mortality incidence of 4% (95% CI: 2–9%) in those without cancer compared to 19% (95% CI: 8–37%) in patients with cancer (p for difference: <0.01). Finally, prevalence of any PH group in patients with cancer was 22% (95% CI: 15–31%). Conclusions: We observed a possible correlation between PH and cancer, with a significant impact on mortality in patients with PH, particularly those with CTEPH. This association suggests the need for a close clinical surveillance for early detection of cancer and PH. Full article
Show Figures

Graphical abstract

Back to TopTop